Professional Documents
Culture Documents
Influenza: Elysha Hussein Sarah Hall Ayesha Sattar
Influenza: Elysha Hussein Sarah Hall Ayesha Sattar
Structure of Virion
HA - hemagglutinin NA - neuraminidase helical nucleocapsid (RNA plus NP protein)
100 n m
M1 protein Influenza virions are SMALL. The average eukaryotic cell diameter is 10,000 nm (10 microns), which is 100 times bigger than the influenza virion diameter.
http://www.med.sc.edu:85/pptvir2002/INFLUENZA-2002.ppt
Influenza Subtypes
Types A & B
3 IMPs
HA NA M2
Type C
1 IMP
HEF Serves functions of both HA and NA
8 Segments of RNA
Responsible for epidemics & pandemics
Influenza strains are subtyped A, B, or C based on the relatedness of the matrix (M1) and nucleoprotein (NP) antigens All 3 subtypes can infect human, subtype A can also infect other mammals and birds Within each subtype, there are many variant strains
Type B
Humans
Type C
Humans Swine
http://www-ermm.cbcu.cam.ac.uk/01002460a.pdf
Matrix 2 (M2)
Tetrameric Protein 10 copies per virion
http://www.biotech.ubc.ca/db/TEACH/BANK/PPT/flu2.ppt
Fusion Schematic
1) HA binds a cell GP at a Sialic Acid Binding Site
http://ubik.microbiol.washington.edu/microm-pabio445/MM_445_lec3_2002_files/MM_445_lec3_2002.ppt
Fusion Schematic
1) HA binds a cell GP at a Sialic Acid Binding Site
Low pH
http://ubik.microbiol.washington.edu/microm-pabio445/MM_445_lec3_2002_files/MM_445_lec3_2002.ppt
Fusion Schematic
1) HA binds a cell GP at a Sialic Acid Binding Site
3) Conformational Change: Hydrophobic binding of HA to vesicle membrane
Low pH
http://ubik.microbiol.washington.edu/microm-pabio445/MM_445_lec3_2002_files/MM_445_lec3_2002.ppt
Fusion Schematic
1) HA binds a cell GP at a Sialic Acid Binding Site
3) Conformational Change: Hydrophobic binding of HA to vesicle membrane
Low pH
4) RNPs are released into cytoplasm for replication and transcription (vRNA and mRNA)
http://ubik.microbiol.washington.edu/microm-pabio445/MM_445_lec3_2002_files/MM_445_lec3_2002.ppt
Hemagglutinin (HA)
IMP: homotrimer of non-covalently linked monomers
There are 15 variants of HA currently identified
Precursor (HA0) is synthesized in the RER & Golgi, then transported to the cell membrane Activated when cleaved into 2 chains (HA1 & HA2) that join by disulfide bond HA1 is critical for initial fusion event
Uses Sialic-acid-containing receptors on host cell glycoproteins. This receptor binding event is followed by endocytosis.
HA Cleavage
Specific cleavage site is a basic sequence of AAs. The site is conserved for specific species. Cleaving enzyme can determine pathogenicity of virus. If the enzyme is ubiquitous in cells, then those cells can make virulent influenza. Humans: Argenine is present at cleavage site
Cleaving enzyme is a tryptase called Clara Only produced in Clara cells, which are only found in upper respiratory tract
Influenza infection is confined to this region of the body
Neuraminidase
IMP: heterotrimer
There are 9 variants currently identified & sequenced
Catalyzes cleavage of ketosidic linkage between sialic acid and adjacent D-galactose or D-galactosamine
HA binds sialic receptors, NA releases virus or progeny virus from receptor
Matrix 2
IMP: Homotetrameric Single pass transmembrane protein Roles in last 2 steps of entry process
Facilitates membrane fusion in endosome
Low pH in endosome activates M2 to open ion channel. Hydrogens enter virus and activate HA to undergo conformational change that results in membrane fusion with endosome
Nomenclature
3 Subtypes, coupled with variance of the antigenicity of surface proteins (HA & NA) and the long history of influenza epidemics necessitate a nomenclature system to catalogue each strain.
A/Moscow/21/99/H3N2
Subtype NP & MI Geographic Origin
Strain Number
Year of Isolation HA & NA Sub-strain
http://www.biotech.ubc.ca/db/TEACH/BANK/PPT/flu2.ppt
Antigenic Shift
Phylogenic evolution that accounts for emergence of new strains of virus Immunologically distinct, novel H/N combinations Genetic reassortment between circulating human and animal strains is responsible for shifts Segmented genome facilitates reassortment Only been observed in type A, since it infects many species
http://www.nlm.nih.gov/medlineplus/ency/imagepages/17237.htm
http://www.lungusa.org/diseases/c&f02/influenza.html#what
Symptoms
Symptoms begin 1-4 days after infection. You can spread the flu before your symptoms start and 3-4 days after your symptoms appear. The following symptoms of the flu can vary depending on the type of virus, a persons age and overall health:
Sudden onset of chills and fever (101 103 degrees F) Sore throat, dry cough Fatigue, malaise Terrible muscle aches, headaches Diarrhea Dizziness
Cold
Rare
Flu
days Headache: Rare Prominent General Aches: Pains Slight Usual Often severe Fatigue: Quite mild Can last up to 2 3 weeks Extreme Exhaustion: Never Early and prominen Stuffy Nose: Common Sometimes Sneezing: Usual Sometimes Sore Throat: Common Sometimes Chest Discomfort: Mild to moderate Common:can becom hacking cough severe
Complications Superinfection
A bacterial superinfection can develop when the influenza virus infects the lungs. The result?
The bacteria that live in the nose and throat can descend to the lungs and cause bacterial pneumonia.
http://www.ecureme.com/atlas/version2001/atlas.asp
Complications in children:
Studies show a link between the development of Reyes syndrome and the use of aspirin for relieving fevers caused by the influenza virus. The disease involves the CNS and the liver and children exhibit symptoms of drowsiness, persistent vomiting and change in personality.
Influenza outbreaks:
Outbreaks are associated with cold weather and therefore occur mostly in the winter months.
A reason for this: the contrast of the cold outdoor air and the heated indoor air can cause the drying of the respiratory tract tissues and render individuals more susceptible to contracting the flu.
Outbreaks are likely to occur among individuals living together in settings such as nursing homes or among people who gather together indoors during the winter months.
Diagnosis:
Individuals with symptoms of influenza should see their doctor for a thorough physical exam. Rapid influenza tests, viral cultures, and serum samples can be used to confirm infection by the influenza virus since the symptoms of the flu are similar to the symptoms caused by other infections.
Viral Cultures:
Samples to be tested by viral cultures need to
be collected from the first four days of infection. The viral culture can be performed from nasopharyngeal or throat swabs, nasal wash, or nasal aspirates. The results are made available within 3 to 10 days.
Serum samples:
Blood samples can be tested for the presence of influenza antibody to diagnose recent infection. Two samples should be collected: one sample within the first week of illness and a second sample 2-4 weeks later. If antibody levels increase from the first to the second sample, influenza infection likely occurred
Surveillance
The global surveillance network determines which strains of the influenza virus will make-up the vaccine. The networks is made up of 200 WHO laboratories in 79 countries and 4 WHO Influenza Collaboratory Centers coordinate the work of the labs. During the course of the year, influenza viruses from patients are sent to these centers. The centers, in conjunction with the FDA Vaccines and Related Biological Products Advisory Committee, make recommendations as to the IV strains they expect to circulating in the next year.
Surveillance Contd:
After both parties agree, the vaccine is manufactured from inactivated viruses.
More on vaccination:
Each years vaccine takes about six months to produce, package and distribute. The influenza vaccine is currently produced in embryonated chicken eggs. Future possibilities: a new growth medium could speed up vaccine production.
http://wdhfs.state.wy.us/epiid/fluvac.htm
Neuraminidase inhibition
http://www.tamiflu.com/hcp/neuramin/neura_index.asp
http://www.tulane.edu/~dmsander/WWW/335/Orthomyxoviruses.html
Historically Speaking
Influenza can be traced as far back as 400 BC In Hippocrates Of the Epidemics, he describes a cough outbreak that occurred in 412 BC in modern-day Turkey at the turn of the autumn season In Hippocrates Of the Epidemics, he describes a cough outbreak that occurred in 412 BC in modern-day Turkey at the turn of the autumn season
412 BC Outbreak
Actual disease that affected the camp is still under debate but is theoretically influenza High communicable rate and autumn season onset are notable characteristics of influenza Death and funerals were a daily spectacle Miasma rising from bodies was fatal to the sick and the sick were fatal to the healthy Hostile ranks were forced to withdraw from the camp
Russia 1830
Spread throughout Russian and westward between 1830 and 1831 By November 1831, the influenza outbreak reached America
Influenza had been regarded as a joke, but the medical profession finally started to realize its severity
By April, virus spread to Europe, China, Japan, Africa, and South America
Characterized as the First Wave high communicability, low lethality Despite low lethality, 800,000 worldwide had died by the summer
Virus killed over 100,000 people per week in some US cities Spread throughout Europe, the Alaskan wilderness, and remote islands of the Pacific By October 1919, flu strain vanished
At least 20,000,000 dead worldwide within 18 months 850,000 Americans
Communicability
Scenario of greatest concern for medical, public health, and political leaders
Lead to a catastrophic epidemic severely taxing societys ability to care for the sick and dying
Focus on developing a pneumonia vaccine, to prevent secondary, often fatal, infections which are facilitated by influenza infection.
References
1. 2. 3. 4. 5. 6. 7. 8. Burnett, Chiu, and Garcea. Structural Biology of Viruses. Oxford: Oxford University Press, 1997. Mahy, Brian WJ. A Dictionary of Virology. 2nd Ed. San Diego: Academic Press, 1997. Fields, Barnard N. et al. Fields Virology vol 1. 3rd Ed. Philadelphia: Lippincott-Raven, 1996. http://www.med.sc.edu:85/pptvir2002/INFLUENZA-2002.ppt Structure and Genome Organization of Influenza Viruses. Expert Reviews in Molecular Medicine. Available: http://wwwermm.cbcu.cam.ac.uk/01002460a.pdf. Cambridge University Press, 2001. Antler, Christine, Boyler, Erin. Who Knew? The Flu and You! From: Biotechnology Laboratory, University of British Columbia. Available Online: http://www.biotech.ubc.ca/db/TEACH/BANK/PPT/flu2.ppt. No date. Isin, Basak, et. al. Functional Motions of Influenza Virus Hemagglutinin: A Structure-Based Analytical Approach. Biophysical Journal. Feb 2002: vol. 82, 569-581. Lagunoff, Michael. Viral Replication. Lecture notes from April 9, 2002 for Microbiology/Pathology 445. University of Washington. Available Online: http://ubik.microbiol.washington.edu/micrompabio445/MM_445_lec3_2002_files/MM_445_lec3_2002.ppt Pinto, Lawrence. The M2 Ion Channel Protein of Influenza Virus A. Detailed Research Summary from Northwestern University. Available Online: http://www.northwestern.edu/neurobiology/faculty/pinto2/pinto_flu.pdf. 8. Feliciano D, et. al. Five-year Experience with PTFE Grafts in Vascular Wounds. American Scientist 2003, 92: 122129. Pandemics and Pandemic Scares in the 20th Century from CDC: Pandemic Influenza [Online] Schoch-Spana M. Implications of Pandemic Influenza for Bioterrorism Response. Clinical Infectious Diseases 2000; 31:1409-13 Puskoor, Rohit et al. Invfluenza Virus Book Chapter. Not yet published.